123 related articles for article (PubMed ID: 37926860)
21. A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma.
Fox E; Busch C; DeBernardo A; Segers B; Gottschalk J; Womer R; Balamuth N; Bagatell R; Balis F
Cancer Chemother Pharmacol; 2021 Jun; 87(6):807-815. PubMed ID: 33677616
[TBL] [Abstract][Full Text] [Related]
22. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.
Heuschkel S; Kretschmann T; Teipel R; von Bonin S; Richter S; Quick S; Alakel N; Röllig C; Balaian E; Kroschinsky F; Knoth H; Bornhäuser M; von Bonin M
Cancer Chemother Pharmacol; 2022 Jan; 89(1):41-48. PubMed ID: 34669022
[TBL] [Abstract][Full Text] [Related]
23. Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia?
Barakat S; Assem H; Salama M; Mikhael N; El Chazli Y
J Egypt Natl Canc Inst; 2022 Apr; 34(1):17. PubMed ID: 35434757
[TBL] [Abstract][Full Text] [Related]
24. Renal dysfunction during and after high-dose methotrexate.
Green MR; Chamberlain MC
Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
[TBL] [Abstract][Full Text] [Related]
25. Effect of Levetiracetam on Time to High-Dose Methotrexate Clearance in Patients With Hematologic Malignancies.
Lou U; Kwok J; Nguyen TA; Zhou A; Luk SO
J Clin Pharmacol; 2020 Mar; 60(3):324-330. PubMed ID: 31729053
[TBL] [Abstract][Full Text] [Related]
26. Prospective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function.
Barreto JN; Reid JM; Thompson CA; Mara KC; Rule AD; Kashani KB; Leung N; Larson TR; McGovern RM; Witzig TE; Barreto EF
Clin Transl Sci; 2022 Jan; 15(1):105-117. PubMed ID: 34378331
[TBL] [Abstract][Full Text] [Related]
27. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.
Jahnke K; Korfel A; Martus P; Weller M; Herrlinger U; Schmittel A; Fischer L; Thiel E;
Ann Oncol; 2005 Mar; 16(3):445-9. PubMed ID: 15653703
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity.
Wiczer T; Dotson E; Tuten A; Phillips G; Maddocks K
J Oncol Pharm Pract; 2016 Jun; 22(3):430-6. PubMed ID: 26152702
[TBL] [Abstract][Full Text] [Related]
29. Rituximab with high-dose methotrexate in primary central nervous system lymphoma.
Kansara R; Shenkier TN; Connors JM; Sehn LH; Savage KJ; Gerrie AS; Villa D
Am J Hematol; 2015 Dec; 90(12):1149-54. PubMed ID: 26414492
[TBL] [Abstract][Full Text] [Related]
30. Addition of low dose acetazolamide as an adjunct in patients undergoing high dose methotrexate is safe and beneficial.
Ku M; Bazargan A; Tam C
Intern Med J; 2020 Mar; 50(3):357-362. PubMed ID: 31403755
[TBL] [Abstract][Full Text] [Related]
31. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
32. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities.
Foster JH; Thompson PA; Bernhardt MB; Margolin JF; Hilsenbeck SG; Jo E; Marquez-Do DA; Scheurer ME; Schafer ES
Cancer Chemother Pharmacol; 2019 Feb; 83(2):349-360. PubMed ID: 30488179
[TBL] [Abstract][Full Text] [Related]
33. Primary central nervous system lymphoma: a single-centre experience of 55 unselected cases.
Hodson DJ; Bowles KM; Cooke LJ; Kläger SL; Powell GA; Laing RJ; Grant JW; Williams MV; Burnet NG; Marcus RE
Clin Oncol (R Coll Radiol); 2005 May; 17(3):185-91. PubMed ID: 15901003
[TBL] [Abstract][Full Text] [Related]
34. Patient selection and tolerability of high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma.
Garwood MJ; Hawkes EA; Churilov L; Chong G
Cancer Chemother Pharmacol; 2020 Jan; 85(1):133-140. PubMed ID: 31848681
[TBL] [Abstract][Full Text] [Related]
35. [Survey of Methotrexate Prescription and Blood Concentration in Patients Treated with High-Dose Methotrexate].
Kobayashi S; Yasu T; Momo K; Ohno N
Gan To Kagaku Ryoho; 2020 Jul; 47(7):1063-1067. PubMed ID: 32668853
[TBL] [Abstract][Full Text] [Related]
36. Identification of Risk Factors in High-Dose Methotrexate-Induced Acute Kidney Injury in Childhood Acute Lymphoblastic Leukemia.
Cheng DH; Lu H; Liu TT; Zou XQ; Pang HM
Chemotherapy; 2018 Apr; 63(2):101-107. PubMed ID: 29672292
[TBL] [Abstract][Full Text] [Related]
37. Acute Kidney Injury with SARS-CoV-2 Infection in Pediatric Patients Receiving High-Dose Methotrexate Chemotherapy: A Report of Three Cases.
Nigro O; Meazza C; Schiavello E; Biassoni V; Puma N; Bergamaschi L; Gattuso G; Sironi G; Livellara V; Papagni G; Massimino M
Children (Basel); 2023 Feb; 10(2):. PubMed ID: 36832467
[TBL] [Abstract][Full Text] [Related]
38. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for high-dose methotrexate associated toxicities in patients with primary central nervous system lymphoma.
Sun K; Tao H; Ding T; Li Z; Qiu X; Zhong M; Wu Z
J Clin Pharm Ther; 2022 Dec; 47(12):2196-2204. PubMed ID: 36259502
[TBL] [Abstract][Full Text] [Related]
40. Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas.
Fleming M; Huang Y; Dotson E; Bond DA; Reneau J; Epperla N; Alinari L; Brammer J; Christian BA; Baiocchi RA; Maddocks K; Sawalha Y
Blood Adv; 2022 Jan; 6(2):460-472. PubMed ID: 34788387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
